-
FEMY Dashboard
- Financials
- Filings
-
Holdings
-
Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Femasys (FEMY)
Company Profile
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 7.61 mm | 7.61 mm | 7.61 mm | 7.61 mm | 7.61 mm | 7.61 mm |
Cash burn (monthly) | 1.97 mm | 90.10 k | 1.80 mm | 1.51 mm | 1.82 mm | 1.45 mm |
Cash used (since last report) | 10.64 mm | 486.06 k | 9.72 mm | 8.16 mm | 9.84 mm | 7.82 mm |
Cash remaining | -3.02 mm | 7.13 mm | -2.11 mm | -544.96 k | -2.23 mm | -213.36 k |
Runway (months of cash) | -1.5 | 79.1 | -1.2 | -0.4 | -1.2 | -0.1 |
13F holders | Current |
---|---|
Total holders | 29 |
Opened positions | 13 |
Closed positions | 3 |
Increased positions | 3 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 2.52 bn |
Total shares | 15.05 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
PMCB PharmaCyte Biotech | 12.71 mm | $11.82 mm |
Vanguard | 825.67 k | $908.23 mm |
CM Management | 425.00 k | $467.50 mm |
Clear Creek Financial Management | 256.37 k | $282.01 mm |
Geode Capital Management | 216.16 k | $237.83 mm |
NTRS Northern Trust | 126.10 k | $138.71 mm |
STT State Street | 56.37 k | $62.01 mm |
RY Royal Bank of Canada | 52.94 k | $58.00 mm |
Citadel Advisors | 40.97 k | $45.07 mm |
BlackRock | 35.68 k | $39.25 mm |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Jan 25 | Kathy Lee-Sepsick | Stock Option Common Stock | Grant | Acquire A | No | No | 1.17 | 262,700 | 307.36 k | 262,700 |
29 Jan 25 | Kathy Lee-Sepsick | Stock Option Common Stock | Grant | Acquire A | No | No | 1.17 | 120,353 | 140.81 k | 120,353 |
29 Jan 25 | Kathy Lee-Sepsick | Stock Option Common Stock | Grant | Acquire A | No | No | 1.17 | 59,849 | 70.02 k | 59,849 |
28 Jan 25 | Daniel Scott Currie | Stock Option Common Stock | Grant | Acquire A | No | No | 1.05 | 140,700 | 147.74 k | 140,700 |
28 Jan 25 | Daniel Scott Currie | Stock Option Common Stock | Grant | Acquire A | No | No | 1.05 | 59,313 | 62.28 k | 59,313 |
28 Jan 25 | Daniel Scott Currie | Stock Option Common Stock | Grant | Acquire A | No | No | 1.05 | 29,184 | 30.64 k | 29,184 |
28 Jan 25 | Christine E Thomas | Stock Option Common Stock | Grant | Acquire A | No | No | 1.05 | 23,600 | 24.78 k | 23,600 |
28 Jan 25 | Christine E Thomas | Stock Option Common Stock | Grant | Acquire A | No | No | 1.05 | 28,682 | 30.12 k | 28,682 |
28 Jan 25 | Christine E Thomas | Stock Option Common Stock | Grant | Acquire A | No | No | 1.05 | 55,090 | 57.84 k | 55,090 |
28 Jan 25 | Dov Elefant | Stock Option Common Stock | Grant | Acquire A | No | No | 1.05 | 114,300 | 120.02 k | 114,300 |